Q-omics provides the consensus-scored C10orf126 profile across patient tissues and cancer cell-line models. C10orf126 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C10orf126 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, C10orf126 RNA expression shows 10,514 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where C10orf126 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C10orf126 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C10orf126 survival associations across molecular data types. C10orf126 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C10orf126 RNA expression–survival associations across cancer types. High C10orf126 expression shows unfavorable associations in LIHC, BRCA, LGG, KICH and BLCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C10orf126 RNA expression.
This table summarizes C10orf126 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for C10orf126. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C10orf126 shows lower tumor expression in KIRP, KICH and LIHC and higher tumor expression in BRCA, UCEC and STAD. The KIRP box plot shows higher C10orf126 RNA expression in normal versus tumor tissue (log2 FC = −1.352, t-test p < 0.001).
This table shows molecular features associated with C10orf126 in patient tissues and cancer cell lines. In patient samples, C10orf126 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
